First patient treated in the UK for the TRIPP-FXX study
Filed with ASX · · 3 pages · English
Earlier from OncoSil Medical
- First Austria-based treatments utilising the OncoSil device
- Prospectus - Entitlement Offer
- Placement and Entitlement Offer to raise up to $7.1 million
- 84 German hospitals can negotiate fee for Oncosil device
- OncoSil receives $1.1m R&D tax incentive
Later from OncoSil Medical
- First patient treated with OncoSil device in Turkiye
- 1st Study in Man Increases Pancreatic Tumor Vascularity
- $5.3 million raised under Entitlement Offer
- Australian institution to invest $2.7 million in OSL
- Successful Treatment with OncoSil Device in Turkiye
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical